Per Hove Thomsen

Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway. / Glenngård, Anna H; Hjelmgren, Jonas; Thomsen, Per Hove; Tvedten, Torbjörn.

I: Nordic Journal of Psychiatry, Bind 67, Nr. 5, 10.2013, s. 351-359.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Glenngård, Anna H ; Hjelmgren, Jonas ; Thomsen, Per Hove ; Tvedten, Torbjörn. / Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway. I: Nordic Journal of Psychiatry. 2013 ; Bind 67, Nr. 5. s. 351-359.

Bibtex

@article{ada070a87b314b4ebbb9238c9f473ca8,
title = "Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway",
abstract = "BACKGROUND: The choice between different attention-deficit/hyperactivity disorder (ADHD) medications depends on different drug attributes. Economic evaluations of drugs often disregard the utility of other attributes compare with the drugs' efficacy.AIMS: The aim of this study was to assess patient's preferences and elicit willingness-to-pay (WTP) for different drug attributes in the treatment of ADHD.METHODS: 285 patients (117 parents for children below 15 years, 52 adolescents 15-17 years and 116 adults aged 18 years and above) from Sweden, Denmark and Norway completed a questionnaire concerning their ADHD drug treatment, and answered questions on their preferences using a discrete choice experiment (DCE). Included attributes were effectiveness, side-effects, dosing and price.RESULTS: Effectiveness was the most important attribute, followed by side-effects and the number of dosings per day (all P < 0.001). The estimated monthly WTP for a drug generating full effectiveness, no side-effects and once-daily dosing was €790 for adolescents and €360 for adults. The estimated WTP for ADHD drugs with characteristics similar to existing drugs on the market was higher or in line with market prices (€37-180 for adolescents and €16-80 for adults). Regarding experience with current treatment, 19% of all patients in the study reported good functioning during the morning, day and evening.CONCLUSIONS: The gap between the monetary valuation of existing products and an optimally valued product suggest that there is room for improvements in the clinical management of ADHD. The results suggest that DCE is a method that can be used to value not only hypothetical scenarios but also can be used to value and distinguish between real-life scenarios.",
keywords = "Adolescent, Adult, Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Child, Choice Behavior, Denmark, Female, Health Services Needs and Demand, Humans, Male, Norway, Patient Preference, Questionnaires, Sweden, Young Adult",
author = "Glenng{\aa}rd, {Anna H} and Jonas Hjelmgren and Thomsen, {Per Hove} and Torbj{\"o}rn Tvedten",
year = "2013",
month = oct,
doi = "10.3109/08039488.2012.748825",
language = "English",
volume = "67",
pages = "351--359",
journal = "Nordic Journal of Psychiatry",
issn = "0803-9488",
publisher = "Taylor & Francis ",
number = "5",

}

RIS

TY - JOUR

T1 - Patient preferences and willingness-to-pay for ADHD treatment with stimulants using discrete choice experiment (DCE) in Sweden, Denmark and Norway

AU - Glenngård, Anna H

AU - Hjelmgren, Jonas

AU - Thomsen, Per Hove

AU - Tvedten, Torbjörn

PY - 2013/10

Y1 - 2013/10

N2 - BACKGROUND: The choice between different attention-deficit/hyperactivity disorder (ADHD) medications depends on different drug attributes. Economic evaluations of drugs often disregard the utility of other attributes compare with the drugs' efficacy.AIMS: The aim of this study was to assess patient's preferences and elicit willingness-to-pay (WTP) for different drug attributes in the treatment of ADHD.METHODS: 285 patients (117 parents for children below 15 years, 52 adolescents 15-17 years and 116 adults aged 18 years and above) from Sweden, Denmark and Norway completed a questionnaire concerning their ADHD drug treatment, and answered questions on their preferences using a discrete choice experiment (DCE). Included attributes were effectiveness, side-effects, dosing and price.RESULTS: Effectiveness was the most important attribute, followed by side-effects and the number of dosings per day (all P < 0.001). The estimated monthly WTP for a drug generating full effectiveness, no side-effects and once-daily dosing was €790 for adolescents and €360 for adults. The estimated WTP for ADHD drugs with characteristics similar to existing drugs on the market was higher or in line with market prices (€37-180 for adolescents and €16-80 for adults). Regarding experience with current treatment, 19% of all patients in the study reported good functioning during the morning, day and evening.CONCLUSIONS: The gap between the monetary valuation of existing products and an optimally valued product suggest that there is room for improvements in the clinical management of ADHD. The results suggest that DCE is a method that can be used to value not only hypothetical scenarios but also can be used to value and distinguish between real-life scenarios.

AB - BACKGROUND: The choice between different attention-deficit/hyperactivity disorder (ADHD) medications depends on different drug attributes. Economic evaluations of drugs often disregard the utility of other attributes compare with the drugs' efficacy.AIMS: The aim of this study was to assess patient's preferences and elicit willingness-to-pay (WTP) for different drug attributes in the treatment of ADHD.METHODS: 285 patients (117 parents for children below 15 years, 52 adolescents 15-17 years and 116 adults aged 18 years and above) from Sweden, Denmark and Norway completed a questionnaire concerning their ADHD drug treatment, and answered questions on their preferences using a discrete choice experiment (DCE). Included attributes were effectiveness, side-effects, dosing and price.RESULTS: Effectiveness was the most important attribute, followed by side-effects and the number of dosings per day (all P < 0.001). The estimated monthly WTP for a drug generating full effectiveness, no side-effects and once-daily dosing was €790 for adolescents and €360 for adults. The estimated WTP for ADHD drugs with characteristics similar to existing drugs on the market was higher or in line with market prices (€37-180 for adolescents and €16-80 for adults). Regarding experience with current treatment, 19% of all patients in the study reported good functioning during the morning, day and evening.CONCLUSIONS: The gap between the monetary valuation of existing products and an optimally valued product suggest that there is room for improvements in the clinical management of ADHD. The results suggest that DCE is a method that can be used to value not only hypothetical scenarios but also can be used to value and distinguish between real-life scenarios.

KW - Adolescent

KW - Adult

KW - Attention Deficit Disorder with Hyperactivity

KW - Central Nervous System Stimulants

KW - Child

KW - Choice Behavior

KW - Denmark

KW - Female

KW - Health Services Needs and Demand

KW - Humans

KW - Male

KW - Norway

KW - Patient Preference

KW - Questionnaires

KW - Sweden

KW - Young Adult

U2 - 10.3109/08039488.2012.748825

DO - 10.3109/08039488.2012.748825

M3 - Journal article

C2 - 23245636

VL - 67

SP - 351

EP - 359

JO - Nordic Journal of Psychiatry

JF - Nordic Journal of Psychiatry

SN - 0803-9488

IS - 5

ER -